Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China

Sun, Liqin1,2; He, Yun1,2; Xu, Liumei1,2; Zhao, Fang1,2; Zhou, Yang1,2; Zhang, Lukun1,2; Peng, Qiaoli1,2; Zhang, Haitao1,2; Zhang, Qiuyue1,2; Cao, Tingzhi1,2; Song, Ying1,2; Wang, Siyuan1,2; Rao, Man1,2; Jia, Xinyun1,2; Liu, Xiaoning1,2; Zhou, Jing1,2; Ju, Bin1,2; Wang, Hui1,2; Liu, Jiaye3

2022-10-01

10.1097/QAI.0000000000003040

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES   影响因子和分区

1525-4135

1077-9450

Background: We aimed to examine the evolution of blood lipids and compare the risk of dyslipidemia between antiretroviral-naive people living with HIV who received tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) (TDF + 3TC + EFV) and those who received coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF). Methods: We retrospectively reviewed the medical records of 2343 antiretroviral-naive people living with HIV who initiated TDF + 3TC + EFV or E/C/F/TAF. A propensity score matching method was used to compare longitudinal changes of blood lipids between the 2 groups. Results: By using 1:3 matching ratio, we included 253 and 91 matched patients in TDF + 3TC + EFV group and E/C/F/TAF group, respectively. The levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol were higher in E/C/F/TAF group than those in TDF + 3TC + EFV group at 3, 6, 9, and 12 months (Wilcoxon test, all Ps < 0.05), except for high-density lipoprotein cholesterol at 9 and 12 months. The cumulative rates of hypercholesterolemia, hypertriglyceridemia, and high LDL-C in PLWH with normal lipid levels in E/C/F/TAF group were higher than those in TDF + 3TC + EFV group (hypercholesterolemia, 59.7% vs 21.5%, P < 0.001; hypertriglyceridemia, 69.5% vs 46.3%, P < 00.001; and high LDL-C, 41.5% vs 14.2%, P < 0.001). Multivariate analysis showed treatment with E/C/F/TAF was associated with a significantly higher risk of hypercholesterolemia [adjusted hazard ratio (HR), 4.12; 95% confidence interval (CI): 2.65 to 6.41], hypertriglyceridemia (adjusted HR, 1.69; 95% CI: 1.18 to 2.43), and high LDL-C (adjusted HR, 4.60; 95% CI: 2.66 to 7.97). Conclusions: We concluded that treatment with E/C/F/TAF resulted in higher risks of dyslipidemia compared with TDF + 3TC + EFV.

hyperlipidemia cardiovascular disease antiretroviral therapy nucleoside reverse transcriptase inhibitor nonnucleoside reverse transcriptase inhibitor integrase strand transfer inhibitor

SCI

英语

第一

Sanming Project of Medicine in Shenzhen[SZSM201512029] ; Guangdong Basic and Applied Basic Research Foundation[2019A1515011197] ; Shenzhen Science and Technology Program[JCYJ20190809115617365] ; Science and Technology Innovation Committee of Shenzhen Municipality[JCYJ20170412151650600]

Immunology ; Infectious Diseases

Immunology ; Infectious Diseases

WOS:000852773800002

LIPPINCOTT WILLIAMS & WILKINS

IMMUNOLOGY

Web of Science

1.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 2, Shenzhen, Guangdong, Peoples R China
3.Shenzhen Univ, Hlth Sci Ctr, Sch Publ Hlth, Shenzhen, Guangdong, Peoples R China

Sun, Liqin,He, Yun,Xu, Liumei,et al. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES,2022,91.

Sun, Liqin.,He, Yun.,Xu, Liumei.,Zhao, Fang.,Zhou, Yang.,...&Liu, Jiaye.(2022).Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES,91.

Sun, Liqin,et al."Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China".JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 91(2022).